Daiichi Sankyo Co Ltd
TSE:4568
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 850
6 148
|
| Price Target |
|
We'll email you a reminder when the closing price reaches JPY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Daiichi Sankyo Co Ltd
Daiichi Sankyo Co Ltd
Other Equity
Daiichi Sankyo Co Ltd
Other Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Other Equity
¥245.7B
|
CAGR 3-Years
29%
|
CAGR 5-Years
22%
|
CAGR 10-Years
5%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Other Equity
¥2.1T
|
CAGR 3-Years
66%
|
CAGR 5-Years
75%
|
CAGR 10-Years
17%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Other Equity
¥237.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
19%
|
|
|
S
|
Shionogi & Co Ltd
TSE:4507
|
Other Equity
¥270.6B
|
CAGR 3-Years
4 385%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Other Equity
¥2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
6%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Other Equity
¥463.3B
|
CAGR 3-Years
41%
|
CAGR 5-Years
37%
|
CAGR 10-Years
11%
|
|
Daiichi Sankyo Co Ltd
Glance View
Daiichi Sankyo Co., Ltd., a cornerstone of Japan's pharmaceutical industry, embarked on its journey in 2005 from the merger of two storied companies, Daiichi Pharmaceutical and Sankyo Co., both with roots stretching back to the early 20th century. They combined their rich histories and expertise to form a global powerhouse in healthcare. Daiichi Sankyo has since developed a compelling narrative in creating innovative pharmaceuticals, with a particular focus on oncology, managing cardiovascular risks, and tackling inflammatory diseases. This dedication is reflected in its flagship product, Enhertu (trastuzumab deruxtecan), a cutting-edge therapy in the field of oncology that has gained considerable global traction and approval for treating HER2-positive cancers. Constantly investing in research and development, the company aims to enhance its portfolio through innovative drugs that fulfill unmet medical needs, thereby driving sustainable growth. The financial engine propelling Daiichi Sankyo forward is fueled by its robust product pipeline and strategic partnerships, such as its collaboration with AstraZeneca. These alliances not only bolster its research capabilities but also extend its market reach, especially in regions where regulatory landscapes can be intricate. While its revenue streams are primarily generated from pharmaceuticals, the company also invests in over-the-counter medications and vaccines, contributing to a diversified revenue base. Daiichi Sankyo’s strategy of maintaining a balanced portfolio, combined with its strategic commitment to pioneering treatments in oncology, aligns with its broader vision of being a leader in the global pharmaceutical arena, translating their scientific discoveries into tangible health solutions worldwide.
See Also
What is Daiichi Sankyo Co Ltd's Other Equity?
Other Equity
245.7B
JPY
Based on the financial report for Sep 30, 2024, Daiichi Sankyo Co Ltd's Other Equity amounts to 245.7B JPY.
What is Daiichi Sankyo Co Ltd's Other Equity growth rate?
Other Equity CAGR 10Y
5%
Over the last year, the Other Equity growth was -12%. The average annual Other Equity growth rates for Daiichi Sankyo Co Ltd have been 29% over the past three years , 22% over the past five years , and 5% over the past ten years .
You don't have any saved screeners yet
